Recombinant Human Albumin (Oryza Sativa)

重组人白蛋白（水稻）

Report date: 2026/02/11 20:01:36

Base Information

Drug NameRecombinant Human Albumin (Oryza Sativa)
Drug Alias NameRecombinant Human Serum Albumin from Oryza Sativa植物源重组人血清白蛋白Recombinant human serum albuminfrom OsrHSA重组人白蛋白注射液（水稻）奥福民 +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionAlbumins replacements
TargetsAlbumins
Therapy Area/IndicationsEdemaFibrosisAscites +[5] 
Global Approved IndicationsHypoalbuminemiaLiver Cirrhosis
Approved Indications in ChinaHypoalbuminemiaLiver Cirrhosis
Original Approved Country/TerritoryMainland China
Original Approved Date2025/07/15
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesWuhan Healthgen Biotechnology Corp
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Healthgen Biotechnology Corp
Inactive CompaniesN/A
Active IndicationsFibrosisAscitesHypoalbuminemia +[4] 
Inactive IndicationsEdema

Other Information

ATC CodeN/A
Related LinksN/A